Integrated BioPharma Inc (INBP) stock
INBPOTCPharmaceutical PreparationsFiscal year ends June 30
$0.18+0.00 (0.00%)
Close on Oct 19, 2026Market cap $5.59MP/E –Yield –
Integrated BioPharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Integrated BioPharma's free cash flow for the twelve months ending Jun 30, 2026 was $895.00K, down 52.2% year over year. For fiscal 2026 it was $895.00K, down 52.2% from the year before. The highest annual figure on record is $3.61M in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $895.00K | -52.2% |
| FY2025 | Jun 30, 2025 | $1.87M | +380.5% |
| FY2024 | Jun 30, 2024 | $390.00K | -65.1% |
| FY2023 | Jun 30, 2023 | $1.12M | -69.0% |
| FY2022 | Jun 30, 2022 | $3.61M | +30.9% |
| FY2021 | Jun 30, 2021 | $2.76M | +144.9% |
| FY2020 | Jun 30, 2020 | $1.13M | – |
| FY2019 | Jun 30, 2019 | -$86.00K | -109.3% |
| FY2018 | Jun 30, 2018 | $921.00K | +1215.7% |
| FY2017 | Jun 30, 2017 | $70.00K | – |
| FY2016 | Jun 30, 2016 | -$703.00K | – |
| FY2015 | Jun 30, 2015 | -$348.00K | -120.5% |
| FY2014 | Jun 30, 2014 | $1.70M | – |
| FY2013 | Jun 30, 2013 | -$1.47M | – |
| FY2012 | Jun 30, 2012 | -$926.00K | -1117.6% |
| FY2011 | Jun 30, 2011 | $91.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$1.34M | -323.5% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $517.00K | +3.4% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $593.00K | +244.8% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $1.13M | +87.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $601.00K | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $500.00K | -61.5% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $172.00K | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $601.00K | -52.9% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$332.00K | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $1.30M | -10.7% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$1.85M | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.28M | +35.4% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$1.20M | -145.1% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.45M | +173.3% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$76.00K | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $942.00K | -52.2% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $2.67M | +370.5% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $532.00K | -53.4% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$1.57M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $1.97M | +5.6% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $567.00K | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.14M | -53.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$818.00K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.87M | +14.6% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$2.27M | -502.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $2.43M | +340.9% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$670.00K | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $1.63M | +183.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $563.00K | – |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $552.00K | -16.5% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -$1.78M | – |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $575.00K | -61.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | -$206.00K | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $661.00K | +49.5% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$1.07M | -204.1% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.50M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$835.00K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $442.00K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.03M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$567.00K | – |
See a number that looks wrong?